Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Lymphoma

Serum nm23-H1 protein as a prognostic factor for indolent non-Hodgkin's lymphoma

Leukemia volume 15, pages 832–839 (2001)Cite this article

Abstract

Standard chemotherapy has been ineffective for improving the poor 10-year survival rate of patients with indolent lymphoma. However, a wider choice of therapeutic modalities has become recently available, including immunotherapy with monoclonal antibodies and allogeneic peripheral blood stem cell transplantation. Accordingly, a sensitive prognostic indicator is required to identify high-risk patients and to help design new therapeutic approaches for them. We previously reported that the serum nm23-H1 protein level was an independent prognostic factor for aggressive lymphoma. The present study was performed to assess the clinical implications of this protein on indolent lymphoma and whether it can be used to classify the aggressiveness of the disease in order to assist in the individualization of therapy. A total of 130 patients with indolent lymphoma were enrolled in this multicenter study. The serum nm23-H1 protein level was significantly higher in patients with indolent lymphoma than in a normal control group. In addition, indolent lymphoma patients with higher nm23-H1 levels had worse overall and progression-free survival rate than those with lower nm23-H1 levels. Therefore, nm23-H1 in serum may be useful for identifying a distinct group of patients at high risk.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Bastion Y, Berger F, Bryon PA, Felman P, Ffrench M, Coiffier B . Follicular lymphoma: assessment of prognostic factors in 127 patients followed for 10 years Ann Oncol 1991 2: (Suppl. 2) 123–134

    Article  PubMed  Google Scholar 

  2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project . A predictive model for aggressive non-Hodgkin's lymphoma: the International NHL Prognostic Factors Project New Engl J Med 1993 329: 987–994

    Article  Google Scholar 

  3. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C . Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy J Clin Oncol 1999 17: 268–276

    Article  CAS  PubMed  Google Scholar 

  4. Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, Zelenetz AD, Tidmarsh GF, Stagg RJ, Kaminski MS . Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas J Clin Oncol 2000 18: 1316–1323

    Article  CAS  PubMed  Google Scholar 

  5. Freedman AS, Takvorian T, Neuberg D, Mauch P, Rabinowe SN, Anderson KC, Soiffer RJ, Spector N, Grossbard M, Robertson MJ, Blake K, Coral F, Canellos GP, Ritz J, Nadler LM . Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study J Clin Oncol 1993 11: 931–936

    Article  CAS  PubMed  Google Scholar 

  6. Okabe-Kado J, Kasukabe T, Honma Y, Hayashi M, Henzel WJ, Hozumi M . Identity of a differentiation inhibiting factor for mouse myeloid leukemia cells with NM23/nucleoside diphosphate kinase Biochem Biophys Res Commun 1992 182: 987–994

    Article  CAS  PubMed  Google Scholar 

  7. Okabe-Kado J, Kasukabe T, Hozumi M, Honma Y, Kimura N, Baba H, Urano T, Shiku H . A new function of Nm23/NDP kinase as a differentiation inhibitory factor, which does not require its kinase activity FEBS Lett 1995 363: 311–315

    Article  CAS  PubMed  Google Scholar 

  8. Aryee DN, Simonitsch I, Mosberger I, Kos K, Mann G, Schlogl E, Potschger U, Gadner H, Radaszkiewicz T, Kovar H . Variability of nm23-H1/NDPK-A expression in human lymphomas and its relation to tumor aggressiveness Br J Cancer 1996 74: 1693–1698

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Niitsu N, Okabe-Kado J, Kasukabe T, Yamamoto-Yamaguchi Y, Umeda M, Honma Y . Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma Blood 1999 94: 3541–3550

    CAS  PubMed  Google Scholar 

  10. Niitsu N, Okabe-Kado J, Nakayama M, Wakimoto N, Sakashita A, Maseki N, Motoyoshi K, Umeda M, Honma Y . Plasma levels of the differentiation inhibitory factor nm23-H1 protein and their clinical implication in acute myelogenous leukemia Blood 2000 96: 1080–1086

    CAS  PubMed  Google Scholar 

  11. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC . A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group Blood 1994 84: 1361–1392

    CAS  PubMed  Google Scholar 

  12. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M . Report of the Committee on Hodgkin's Disease Staging Classification Cancer Res 1971 31: 1860–1861

    CAS  PubMed  Google Scholar 

  13. Pui C-H, Ip SH, Kung P, Dodge RK, Berard CW, Crist WM, Murphy SB . High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma Blood 1987 70: 624–628

    CAS  PubMed  Google Scholar 

  14. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481

    Article  Google Scholar 

  15. Wilcoxon F . Individual comparisons by ranking methods Biomet Bull 1945 1: 80–83

    Article  Google Scholar 

  16. Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 1966 50: 163–170

    CAS  PubMed  Google Scholar 

  17. Cox DR . Regression models and life tables J Stat Soc Br 1972 34: 187–202

    Google Scholar 

  18. Coiffier B . How should prognostic factors influence therapy in follicular lymphoma? Ann Oncol 1991 2: 619–620

    Article  CAS  PubMed  Google Scholar 

  19. Horning SJ, Rosenberg SA . The natural history of untreated low-grade non-Hodgkin's lymphomas N Engl J Med 1984 311: 1471–1475

    Article  CAS  PubMed  Google Scholar 

  20. Maloney DG, Grillo-Lopez AJ, White CA, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R . IDEC-C2B8 (Rituximab) antibody CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Blood 1997 90: 2188–2195

    CAS  PubMed  Google Scholar 

  21. Lopez-Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E, Rozman C . Applicability of the international index for aggressive lymphomas to patients with low-grade lymphoma J Clin Oncol 1994 12: 1343–1348

    Article  CAS  PubMed  Google Scholar 

  22. Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, Malpas JS, Lister TA . Follicular lymphoma: prognostic factors for response and survival J Clin Oncol 1986 4: 1470–1480

    Article  CAS  PubMed  Google Scholar 

  23. Griffin NR, Howard MR, Quirke P, O'Brien CJ, Child JA, Bird CC . Prognostic indicators in centroblastic-centrocytic lymphoma J Clin Pathol 1988 451: 866–870

    Article  Google Scholar 

  24. Litam P, Swan S, Cabanillas F, Tucker SL, McLaughlin P, Hagemeister FB, Rodriguez MA, Velasquez WS . Prognostic value of serum beta2-microglobulin in low-grade lymphoma Ann Intern Med 1991 114: 855–860

    Article  CAS  PubMed  Google Scholar 

  25. Cameron DA, Leonard RCF, Mao J-H, Prescott RJ . Identification of prognostic groups in follicular lymphoma Leuk Lymphoma 1993 10: 89–99

    Article  CAS  PubMed  Google Scholar 

  26. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, Sobel HE . Evidence for a novel gene associated with low tumor metastatic potential J Natl Cancer Inst 1988 80: 200–204

    Article  CAS  PubMed  Google Scholar 

  27. Gilles AM, Presecan E, Vonica A, Lascu I . Nucleoside diphosphate kinase from human erythrocytes J Biol Chem 1991 266: 8784–8789

    CAS  PubMed  Google Scholar 

  28. Lombardi D, Lacombe ML, Paggi MG . nm23: unraveling its biological function in cell differentiation J Cell Physiol 2000 182: 144–149

    Article  CAS  PubMed  Google Scholar 

  29. Yokoyama A, Okabe-Kado J, Sakashita A, Maseki N, Kaneko Y, Hino K, Tomoyasu S, Tsuruoka N, Kasukabe T, Honma Y . Differentiation inhibitory factor nm23 as a new prognostic factor in acute monocytic leukemia Blood 1996 88: 3555–3561

    CAS  PubMed  Google Scholar 

  30. Okabe-Kado J, Kasukabe T, Honma Y . Differentiation inhibitory factor Nm23 as a prognostic factor for acute myeloid leukemia Leuk Lymphoma 1998 32: 19–28

    Article  CAS  PubMed  Google Scholar 

  31. Litam P, Swan F, Cabanillas F, Tucker SL, McLaughlin P, Hagemeister FB, Rodriguez MA, Velasquez WS . Prognostic value of serum beta-2 microglobulin in low-grade lymphoma Ann Intern Med 1991 114: 855–860

    Article  CAS  PubMed  Google Scholar 

  32. Fayad L, Cabanillas F, Talpaz M, McLaughlin P, Kurzrock R . High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma Leuk Lymphoma 1998 30: 563–571

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the Department of Immunology, SRL Inc (Tokyo, Japan) for measuring the serum nm23-H1 protein levels.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Kitasato University School of Medicine, Kanagawa, Japan

    N Niitsu

  2. Research Institute, Saitama Cancer Center, Saitama, Japan

    N Niitsu, J Okabe-Kado & Y Honma

  3. Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, Japan

    M Okamoto & M Hirano

  4. Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba, Japan

    T Takagi

  5. Toyama Prefectural Central Hospital, Toyama, Japan

    T Yoshida

  6. First Department of Internal Medicine, Niigata University School of Medicine (Adult Lymphoma Treatment Study Group), Niigata, Japan

    S Aoki

Authors
  1. N Niitsu
    View author publications

    Search author on:PubMed Google Scholar

  2. M Okamoto
    View author publications

    Search author on:PubMed Google Scholar

  3. J Okabe-Kado
    View author publications

    Search author on:PubMed Google Scholar

  4. T Takagi
    View author publications

    Search author on:PubMed Google Scholar

  5. T Yoshida
    View author publications

    Search author on:PubMed Google Scholar

  6. S Aoki
    View author publications

    Search author on:PubMed Google Scholar

  7. Y Honma
    View author publications

    Search author on:PubMed Google Scholar

  8. M Hirano
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Niitsu, N., Okamoto, M., Okabe-Kado, J. et al. Serum nm23-H1 protein as a prognostic factor for indolent non-Hodgkin's lymphoma. Leukemia 15, 832–839 (2001). https://doi.org/10.1038/sj.leu.2402105

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.leu.2402105

Keywords

This article is cited by

Search

Advanced search

Quick links